MedTrace Logo

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT01975324 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-01-25

No results posted yet for this study

Summary

Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.

Conditions

  • Non Arteritic Ischemic Optic Neuropathy

Interventions

DRUG

dalfampridine

dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks

DRUG

Placebo

placebo (sugar pill) twice a day for two weeks

Sponsors & Collaborators

  • Acorda Therapeutics

    collaborator INDUSTRY

  • Neuro-Ophthalmologic Associates, PC

    lead OTHER

Principal Investigators

  • Mark L Moster, MD · Neuro-Ophthalmologic Associates, PC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01975324 on ClinicalTrials.gov